Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 3/2009

01-03-2009 | original article

Does CT Influence the Decision to Perform Colectomy in Patients with Severe Ulcerative Colitis?

Authors: Andre da Luz Moreira, Jon D. Vogel, Mark Baker, Isabella Mor, Ren Zhang, Victor Fazio

Published in: Journal of Gastrointestinal Surgery | Issue 3/2009

Login to get access

Abstract

Purpose

The purpose of this study was to evaluate the impact of abdominal computerized tomography (CT) on the decision to perform colectomy in patients with severe acute ulcerative colitis (SAC).

Methods

Patients with SAC admitted to a single hospital between 2002 and 2007 were reviewed. The criteria for SAC were ≥6 bloody bowel movements per day plus fever >37.8°C, pulse >90, or hemoglobin <10.5 g/dL. Study patients were given a SAC score of 2–4 based on these criteria. Clinical and laboratory parameters, medication use, abdominal X-ray, and endoscopic findings in SAC patients who did or did not have an abdominal CT were compared. Chi-squared, Fisher exact test, and Wilcoxon rank sum test were used as appropriate.

Results

Ninety-two consecutive patients with SAC were evaluated. CT was performed in 26 (28%). The SAC score, laboratory values, abdominal X-ray, and endoscopic findings were similar in patients who did or did not have a CT. Colectomy was performed in 32 (48%) and 10 (38%) patients who did or did not have a CT, respectively (p = 0.4). The CT findings were similar in patients who required colectomy and those who did not require colectomy. In two (8%) of the patients who underwent CT, the CT findings clearly influenced the decision to perform or defer colectomy.

Conclusion

CT has a minor impact on the decision to perform colectomy in patients with severe acute ulcerative colitis.
Literature
2.
go back to reference Prantera C, Lorenzetti R, Cerro P, Davoli M, Brancato G, Fanucci A. The plain abdominal film accurately estimates extent of active ulcerative colitis. J Clin Gastroenterol. 1991;13(2):231–234.PubMed Prantera C, Lorenzetti R, Cerro P, Davoli M, Brancato G, Fanucci A. The plain abdominal film accurately estimates extent of active ulcerative colitis. J Clin Gastroenterol. 1991;13(2):231–234.PubMed
4.
go back to reference Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955;2(4947):1041–1048.PubMedCrossRef Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955;2(4947):1041–1048.PubMedCrossRef
5.
go back to reference Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985;89(5):1005–1013.PubMed Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 1985;89(5):1005–1013.PubMed
7.
8.
go back to reference Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in oxford from 2000 to 2006. Aliment Pharmacol Ther. 2007;25(9):1055–1060.PubMedCrossRef Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in oxford from 2000 to 2006. Aliment Pharmacol Ther. 2007;25(9):1055–1060.PubMedCrossRef
13.
go back to reference Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134(3):688–695.PubMed Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134(3):688–695.PubMed
16.
go back to reference Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double blind, placebo controlled, dose ranging trial. Gut. 2006;55(11):1568–1574. doi:10.1136/gut.2005.089854.PubMedCrossRef Van Assche G, Sandborn WJ, Feagan BG, et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomized, double blind, placebo controlled, dose ranging trial. Gut. 2006;55(11):1568–1574. doi:10.​1136/​gut.​2005.​089854.PubMedCrossRef
22.
go back to reference Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629.PubMed Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625–1629.PubMed
Metadata
Title
Does CT Influence the Decision to Perform Colectomy in Patients with Severe Ulcerative Colitis?
Authors
Andre da Luz Moreira
Jon D. Vogel
Mark Baker
Isabella Mor
Ren Zhang
Victor Fazio
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Journal of Gastrointestinal Surgery / Issue 3/2009
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-008-0732-3

Other articles of this Issue 3/2009

Journal of Gastrointestinal Surgery 3/2009 Go to the issue